Press release
Gilead Announces Partial Clinical Hold for Magrolimab Studies in AML
– Enrolled Patients May Continue Receiving Study Medicine – – Studies in Solid Tumors Unaffected – FOSTER CITY, Calif.--(BUSINESS WIRE)-- Gilead Sciences,
About this update from Gilead Sciences, Inc.
[{"type":"text","content":"\n– Enrolled Patients May Continue Receiving Study Medicine –\n\n\n– Studies in Solid Tumors Unaffected –\n\n\n FOSTER CITY, Calif.--(BUSINESS WIRE)--\nGilead Sciences, Inc. (Nasdaq: GILD) today announced that the U.S. Food and Drug Administration (FDA) has placed a partial clinical hold on the initiation of new patients in U.S. studies evaluating magrolimab to treat acute myeloid leukemia (AML).\n\n\nThe FDA action follows the previously announced discontinuation of the Phase 3 ENHANCE study of magrolimab in higher-risk myelodysplastic syndromes (HR-MDS).\n\n\nEffective immediately, screening and enrollment of new study participants under the U.S. investigational new drug application (IND 147229) and U.S. Expanded Access Program will be paused. Patients already enrolled in AML clinical studies may continue to receive treatment and be monitored, according to the current study protocol. Global regulatory authorities and clinical trial investigators involved in the studies have been informed of the FDA’s decision. Studies of magrolimab in solid tumors continue without any impact from the FDA action.\n\n\nGilead is working with regulatory authorities to determine next steps to release the partial clinical hold for new patient enrollment in the magrolimab AML studies.\n\n\nMagrolimab is an investigational agent and has not been approved anywhere globally. Its safety and efficacy have not been established.\n\n\nAbout Magrolimab\n\n\nMagrolimab is a potential first-in-class investigational anti-CD47 immunotherapy. The primary mechanism of action of magrolimab is to block the inhibitory CD47-signal regulatory protein (SIRPα) interaction, enhancing the ability of macrophages and other phagocytes to identify and destroy foreign and malignant cells, with the goal of blocking the “don’t eat me” signal used by cancer cells. Magrolimab is being developed as a potential treatment for AML, myeloid malignancies, lymphoma, myeloma, head and neck cancer, colorectal cancer, lung cancer, and breast cancer. More information about clinical trials with magrolimab is available at www.clinicaltrials.gov.\n\n\nAbout Gilead Sciences\n\n\nGilead Sciences, Inc. is a biopharmaceutical company that has pursued and achieved breakthroughs in medicine for more than three decades, with the goal of creating a healthier world for all people. The company is committe...